Drug intelligence / Profile preview

BSEM-130

Development stage: Preclinical
Lead developer: Nesvik Pharmaceuticals

Overview

BSEM-130 is a reformulated drug compound acquired by BioStem Technologies' subsidiary Nesvik Pharmaceuticals from CCM Pharma Solutions in 2018, targeted for the treatment of **schizophrenia**. Specific details on its mechanism of action, active ingredients, or formulation are not publicly disclosed in available sources. It is part of a series of reformulated compounds (BSEM-120, BSEM-125, BSEM-130, BSEM-135) designed to provide increased efficacy or improved properties at Nesvik's facility, with an updated U.S. FDA establishment registration reflecting this new product development.[1][4][10]

Beyond the preview

Go deeper on BSEM-130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSEM-130.

Explore the full profile